Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

Cancer Research

Volumn 64, Issue 11, 2004, Pages 3958-3965

  Rabindran, Sridhar K ^a,b   Discafani, Carolyn M ^a   Rosfjord, Edward C ^a   Baxter, Michelle ^a   Floyd, M Brawner ^a   Golas, Jonathan ^a   Hallett, William A ^a   Johnson, Bernard D ^a   Nilakantan, Ramaswamy ^a   Overbeek, Elsebe ^a   Reich, Marvin F ^a   Shen, Ru ^a   Shi, Xiaoqing ^a   Tsou, Hwei Ru ^a   Wang, Yu Fen ^a   Wissner, Allan ^a  

^a WYETH RESEARCH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HKI 272; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CELL CYCLE G0 PHASE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; PHOSPHORYLATION; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2542582261     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2868     Document Type: Article

References (44)

1. Olayioye MA, Neve RN, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Reviews Mol Cell Biol 2001;2:127-37.
3. Hynes NE, Stern DF. The biology of ErbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
4. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413-28.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC) 1987;235:177-82.
6. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC) 1989;244:707-12.
7. Scheurle D, Jahanzeb M, Aronsohn RS, Watzek L, Narayanan R. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Herceptest. Anticancer Res 2000;20:2091-6.
8. Cox G, Vyberg M, Melgaard B, Askaa J, Oster A, O'Byrne KJ. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 2001;92:480-3.
9. Bunn PA Jr, Helfrich B, Soriano AF, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001;7:3239-50.
10. Koeppen HKW, Wright BD, Burt AD, et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 2001;38:96-104.
11. Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (p185) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001;7:2643-7.
12. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
13. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 2001;344:783-92.
14. Mass RD, Press M, Anderson S, Murphy M, Slamon DJ. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 2001;20:22.
15. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Non-clinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70.
16. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy for solid tumors. Am J Pathol 1997;151:1523-30.
17. Izumi Y, Xu L, diTomaso E, Fukumura D, Jain RK. Herceptin acts as an antiangiogenic cocktail. Nature (Lond.) 2002;416:279-80.
18. Wissner A, Overbeek E, Reich MF, et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of orally active irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 2003;46:49-63.
19. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8.
20. erbB4. a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993;90:1746-50,
21. Wissner A, Berger DM, Boschelli DH, et al. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J Med Chem 2000;43:3244-56.
22. Fry DW, Bridges AJ, Denny WA, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998;95:12022-7.
23. HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
24. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER-2-driven signaling and suppresses the growth of HER-2-overexpressing tumor cells. Cancer Res 2001;7184-8.
25. Motoyama AB, Hynes NE, Lane HA. The efficacy of erbB receptor-targeted anti-cancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002;62:3151-8.
26. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst (Bethesda) 2001;93:1852-7.
27. Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997;15:1-8.
28. Hung MC, Lau YK. Basic science of Her-2/neu: a review. Semin Oncol 1999;26: 51-9.
29. 1-phase cell cycle machinery. Bioessays 2000;22:818-26.
30. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994;79:573-82.
31. 1-phase progression. Genes Dev 1999;13:1501-2.
32. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
33. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
34. Morin MJ. From oncogene to drug: Development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 2000;19:6574-83.
35. Ciardello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
36. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499-512.
37. Drucker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002;1:31-6.
38. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
39. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER-1) tyrosine kinase inhibitor ZD 1839 (Iressa) inhibits HER-2/neu (ErbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95.
40. Moyer JD, Barbacci EG, lwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48.
41. Allen LF, Leneham PF, Eiseman IA, Elliot WL, Fry DW. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002;29(Suppl 11):11-21.
42. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of normal human and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
43. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human prostate carcinoma. Cancer Res 2000;60: 2996-35.
44. Barbacci EG, Pustilnik LR, Rossi AMK, et al, The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Res 2003;63:4450-9.